Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.12USD
1:11pm EDT
Change (% chg)

$-0.10 (-4.71%)
Prev Close
$2.23
Open
$2.21
Day's High
$2.23
Day's Low
$2.09
Volume
500,147
Avg. Vol
496,925
52-wk High
$4.09
52-wk Low
$1.41

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €295.91
Shares Outstanding(Mil.): 156.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.53 17.08
EPS (TTM): -- -- --
ROI: -- 13.79 11.26
ROE: -- 16.64 15.09

BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

* Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​

Oct 12 2017

BRIEF-Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

* Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

Oct 10 2017

BRIEF-Antares Pharma entered sales agreement with cowen and co to offer, sell shares of its common stock, par value $0.01/share- SEC Filing

* Antares Pharma-on Aug 11,entered sales agreement with Cowen and Company under which co may offer, sell shares of its common stock,par value $0.01/share

Aug 11 2017

BRIEF-Antares Pharma Q2 loss per share $0.02

* Antares pharma reports second quarter 2017 operating and financial results

Aug 08 2017

BRIEF-Antares Pharma announces debt financing from Hercules Capital

* Antares Pharma announces debt financing from Hercules Capital

Jun 07 2017

BRIEF-Antares Pharma files $200 mln mixed shelf

* Files for mixed shelf of up to $200 million - sec filing Source text for Eikon: Further company coverage:

May 09 2017

BRIEF-Antares Pharma reports Q1 loss per share $0.03

* Antares Pharma reports first quarter 2017 operating and financial results

May 09 2017

Earnings vs. Estimates

No consensus analysis data available.